ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0656

A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis

Philip Robinson1, Nicola Dalbeth2, Chris Frampton3, Tony Merriman3, Amanda Phipps-Green3 and Peter Donovan4, 1University of Queensland, Herston, Queensland, Australia, 2University of Auckland, Auckland, New Zealand, 3University of Otago, Dunedin, New Zealand, 4Royal Brisbane & Women's Hospital, HERSTON, Queensland, Australia

Meeting: ACR Convergence 2020

Keywords: gout, Health policy

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: Metabolic & Crystal Arthropathies Poster

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Intake of sugar is associated with increased incident gout. Sugar taxes have been effective at reducing the intake of sugar in several jurisdictions. We aimed to model the impact of a sugar tax on incident gout (assuming causality through increased serum urate levels and a consequent increase in incident gout), quality adjusted life years (QALY) lost and the excess economic cost of new incident gout.

Methods: We modelled the effect of a sugar tax on incident gout in the US population (n=330M) on the study by Choi and colleagues (Arthritis Care & Research 2008;59:109-116). Our model assumptions were a 20% ad velorum (value of the item) taxation level, a price elasticity of -0.95 (defined as the percentage change in the quantity demanded over the percentage chance in price). A passthrough rate of 100% (the amount of tax passed through from the manufacturer to the consumer), a 2.5% per annum discount rate, healthcare inflation rate of 6.5% per annum, and a marginal disutility rate of 0.05 (this is the impact on QALY of a diagnosis of gout). We modelled incident gout rates using the Atherosclerosis Risk in Communities Study (ARIC), Coronary Artery Risk Development in Young Adults Study (CARDIA), and both the Original and Offspring cohorts of the Framingham Heart Studies (FHS). We modelled 3, 5, 10 and 15 year incident gout from < 3.0mg/dL up to 6mg/dL in 0.1mg/dl increments. Our outcomes were incident gout, increases in QALY and economic savings from the reduced gout. In modelling all time points we simulated death using US life tables. We assumed a societal perspective for costs (i.e. costs of treatment were considered regardless to whom they accrue), and a marginal cost of gout over non-gout of US$6,560 per annum. We undertook sensitivity analyses of key input parameters. We did not model the revenue to the government of the sugar tax.

Results: We fitted linear models to the raw incident gout rates from < 3mg/dL to 6mg/dL from the combined cohorts. This enabled fine scale prediction of the effect of sugar tax on reducing SU and consequent incident gout.

We found a reduction in incident gout was achievable (n=84,830) with a 20% ad velorum sugar tax over 15 years (Table 1). Based on this reduction in incident gout we were also able to model a saving of 26,398 QALY over 15 years. This led to a saving of 3.15B in net present value.

Sensitivity analyses demonstrated the model was robust to changes in key inut variables.

Conclusion: Assuming a causal relationship, based purely on the reduction in incident gout, QALY savings and economic savings, we provide evidence supporting a sugar tax to be an effective public health measure to address the growing incidence of gout. The reduction in gout and the consequent savings of QALY and costs should be included when considering the implementation of a sugar tax.

Table 1: Main model Results


Disclosure: P. Robinson, Novartis, 2, 5, 8, UCB, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 5, Pfizer, 5, Abbvie, 5, 8, BMS, 9; N. Dalbeth, AstraZeneca, 1, 2, Abbvie, 1, Arthrosi, 1, Dyve BioSciences, 1, Selecta, 1, Janssen, 1; C. Frampton, None; T. Merriman, None; A. Phipps-Green, None; P. Donovan, None.

To cite this abstract in AMA style:

Robinson P, Dalbeth N, Frampton C, Merriman T, Phipps-Green A, Donovan P. A Sugar Tax Results in Reduced Incident Gout, Quality Adjusted Life Years Lost and Economic Cost from Gout: A Health Economic Analysis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-sugar-tax-results-in-reduced-incident-gout-quality-adjusted-life-years-lost-and-economic-cost-from-gout-a-health-economic-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-sugar-tax-results-in-reduced-incident-gout-quality-adjusted-life-years-lost-and-economic-cost-from-gout-a-health-economic-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology